A psilocybin dose induces brain-wide rewiring, reducing cortical feedback loops and strengthening sensory-to-action pathways, providing a mechanism for anti-rumination effects and altered perception‑action coupling.

This network reorganization offers mechanistic insight into psychedelic antidepressant effects by shifting information processing away from self-focused rumination toward externally driven processing, with potential to influence drug-evoked plasticity through targeted circuit engagement during treatment.

Specifically, psilocybin weakens recurrent cortico-cortical feedback linked to negative rumination and strengthens connections from sensory areas to subcortical regions that govern action.

A single psilocybin dose produces lasting, network-specific rewiring in the mouse cortex, notably strengthening sensory inputs to dorsal medial prefrontal cortex pyramidal tract neurons and weakening inputs to intratelencephalic neurons in cortico-cortical loops for at least a month.

In mice, researchers injected psilocybin into frontal cortical pyramidal neurons and used trans-synaptic rabies labeling to map connected neurons for imaging a week later.

Independent experts affirm the relevance of these network-specific changes and emphasize careful technique and interpretation in tracing neural connections as the work aims to inform psychedelic-based therapies.

Earlier work by the same team showed psilocybin triggers rapid structural plasticity, including dendritic spine growth after a single dose, supporting durable brain changes after treatment.

The study employed viral tracing and a 3D brain atlas to map inputs to pyramidal tract and intratelencephalic neurons, delivering detailed network-level insight into psilocybin‑induced cortical reshaping.

Lead author Quan Jiang and senior author Alex Kwan, renowned Cornell researchers, focus on how psychedelics rewire brain circuitry to support depression therapy.

Published in Cell on December 5, 2025, the study contributes to ongoing work on how psychedelics reshape neural networks to alleviate depressive symptoms.

Researchers frame these results as a step toward steering drug-induced plasticity, with implications for future drug design and delivery; no direct company funding reported for the study.

Long-lasting changes depend on neural activity during the acute dose; chemogenetic silencing of retrosplenial-to-anterior cingulate projections before psilocybin blocks later increases in this pathway, showing context matters for enduring outcomes.

The long-term effects arise from an interaction between chemical action and neural activity during the experience, underscoring treatment context and subjective experience in therapy.

The strongest input increase occurs from the retrosplenial cortex to the anterior cingulate, potentially linking altered self-referential processing to therapeutic effects.

The researchers used a rabies-virus mapping approach to reveal whole-brain rewiring related to depression, not just localized effects.

Findings suggest plasticity after psilocybin can be steered by modulating activity in specific brain regions, offering avenues to optimize positive rewiring and minimize adverse plasticity.

Changes center on pathways with increased sensory input to pyramidal tract neurons and reduced input from insula and basolateral amygdala, while intratelencephalic inputs show weakened recurrent loops.